1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Prostatic Neoplasms, Castration-Resistant in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, C; Li, L; Li, M; Liu, Y; Mao, Y; Song, S; Wang, Z; Xu, B; Yu, G; Zhou, L | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indoles; Male; Mice; Paclitaxel; PC-3 Cells; Platelet Activating Factor; Prostatic Neoplasms, Castration-Resistant; Up-Regulation | 2020 |